Immune checkpoint inhibition (ICI) has revolutionized cancer treatment; however, only a subset of patients benefit long term. Therefore, methods for identification of novel checkpoint targets and development of therapeutic interventions against them remain a critical challenge. Analysis of human genetics has the potential to inform more successful drug target discovery. We used genome-wide association studies of the 23andMe genetic and health survey database to identify an immuno-oncology signature in which genetic variants are associated with opposing effects on risk for cancer and immune diseases. This signature identified multiple pathway genes mapping to the immune checkpoint comprising CD200, its receptor CD200R1, and the downstream adapter protein DOK2. We confirmed that CD200R1 is elevated on tumor-infiltrating immune cells isolated from cancer patients compared to the matching peripheral blood mononuclear cells. We developed a humanized, effectorless IgG1 antibody (23ME-00610) that bound human CD200R1 with high affinity (K D <0.1 nM), blocked CD200 binding, and inhibited recruitment of DOK2. 23ME-00610 induced T-cell cytokine production and enhanced T cell-mediated tumor cell killing in vitro. Blockade of the CD200:CD200R1 immune checkpoint inhibited tumor growth and engaged immune activation pathways in an S91 tumor cell model of melanoma in mice.
CD73 (ecto-5′-nucleotidase) has emerged as an attractive target for cancer immunotherapy of many cancers. CD73 catalyzes the hydrolysis of adenosine monophosphate (AMP) into highly immunosuppressive adenosine that plays a critical role in tumor progression. Herein, we report our efforts in developing orally bioavailable and highly potent small-molecule CD73 inhibitors from the reported hit molecule 2 to lead molecule 20 and then finally to compound 49. Compound 49 was able to reverse AMP-mediated suppression of CD8+ T cells and completely inhibited CD73 activity in serum samples from various cancer patients. In preclinical in vivo studies, orally administered 49 showed a robust dose-dependent pharmacokinetic/pharmacodynamic (PK/PD) relationship that correlated with efficacy. Compound 49 also demonstrated the expected immune-mediated antitumor mechanism of action and was efficacious upon oral administration not only as a single agent but also in combination with either chemotherapeutics or checkpoint inhibitor in the mouse tumor model.
Introduction: High adenosine (ADO) in the tumor microenvironment suppresses the immune response against cancer cells by inhibiting immune effector functions and promoting the development of immunosuppressive cells. Extracellular ADO can be generated from ATP released by cells undergoing stress or death through the combined actions of the ecto-nucleotidases CD39 (ATP to AMP) and CD73 (AMP to ADO). Inhibition of ADO production via CD73 is a promising therapeutic approach for the treatment of cancer. Methods: The potency of CB-708 was evaluated against recombinant CD73 and CD73-expressing cells using a malachite green assay. Selectivity against related ecto-nucleotidases was also assessed. Inhibition of CD73 in plasma was measured using LC/MS to assess conversion of 15N5-AMP into 15N5-ADO. The ability to reverse AMP-mediated immune suppression of human CD8+ T cells was determined by adding exogenous AMP during T cell activation. T cell proliferation was assayed by flow cytometry and cytokine levels were measured by ELISA. The EG7 syngeneic tumor model was used to assess the therapeutic effect of CB-708. Results: CB-708 is an orally bioavailable small molecule inhibitor that can potently inhibit both soluble human CD73 (IC50 = 170 pM) and cell-bound human CD73 (IC50 = 210 pM), but does not inhibit human CD39 (IC50>10 µM), ENTPD2 (IC50>10 µM), nor ENTPD3 (IC50>10 µM). CB-708 retained high potency in the presence of plasma and reversed AMP-mediated suppression of human CD8+ T cell proliferation and production of IFNγ (EC50 = 4.5 nM) and granzyme B (EC50 = 5.6 nM) in vitro. Orally administered CB-708 had dose-dependent single-agent tumor growth inhibition in the EG7 mouse syngeneic tumor model and that was associated with pharmacodynamic inhibition of plasma CD73. Enhanced tumor growth inhibition was observed when anti-PD-L1 was combined with a highly related analog of CB-708 in the EG7 model. Conclusion: CB-708 is an orally bioavailable and highly potent small molecule inhibitor of CD73. CB-708 reverses the immunosuppressive effects of AMP-derived ADO in vitro and in vivo and leads to anti-tumor activity as a monotherapy. CB-708 is expected to enter clinical development in 2019. Citation Format: Clarissa C. Lee, Deepthi Bhupathi, Roland J. Billedeau, Jason Chen, Lijing Chen, Ethan D. Emberley, Matthew I. Gross, Tony Huang, Weiqun Li, Yong Ma, Andrew L. Mackinnon, Amani Makkouk, Gisele M. Marguier, Silinda Neou, Francesco Parlati, Natalija Sotirovska, Timothy F. Stanton, Susanne M. Steggerda, Jing Zhang, Winter Zhang, Jim Li. Reversal of adenosine-mediated immune suppression by CB-708, an orally bioavailable and potent small molecule inhibitor of CD73 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4134.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.